REVIEW ARTICLE

A Review on Usage of Artificial Intelligence for Early Detection and Management of Alzheimer's Disease

Ismail Y *[1], Vijaya Kumar Voleti[2]

[1]*Associate Professor, Crescent School of Pharmacy, B.S. Abdur Rahman Crescent Institute of Science and Technology, Vandalur, Chennai Tamil Nadu, India*
[2]*Assistant Professor, School of Pharmacy, Sathyabama Institute of Science and Technology, Chennai Tamil Nadu, India*

Publication history: Received on 25th July; Revised on 1st August; Accepted on 11th August 2024

Article DOI: 10.69613/06tz7453

Abstract: Artificial Intelligence (AI) has emerged as a powerful tool in Alzheimer's disease (AD) research and clinical practice. This review discusses about the recent advances in AI applications for AD, focusing on neuroimaging analysis, biomarker discovery, cognitive assessment, and predictive modeling. AI techniques, particularly deep learning algorithms, have significantly improved the accuracy and efficiency of brain imaging interpretation, enabling earlier detection of AD-related structural and functional changes. In biomarker research, AI has accelerated the identification of novel blood-based and CSF markers, potentially leading to less invasive and more cost-effective diagnostic methods. AI-driven cognitive assessment tools, including computerized tests and speech analysis, offer more sensitive measures of cognitive decline. Additionally, AI-based predictive models integrating multiple data types show promise in personalized risk assessment and disease progression forecasting. Despite these advancements, challenges remain in data standardization, model interpretability, and ethical considerations. This review explains about the current state of AI in AD research, its potential impact on patient care, and areas requiring further investigation to fully realize the benefits of AI in combating Alzheimer's disease.

Keywords: Alzheimer's disease; Artificial Intelligence; Machine Learning; Neuroimaging; Predictive Modeling.

1. Introduction

Alzheimer's disease (AD) is a progressive neurodegenerative disorder that has emerged as one of the most pressing health challenges of the 21st century. Characterized by cognitive decline, memory loss, and behavioral changes, AD affects millions of individuals worldwide, with its prevalence expected to triple by 2050 [1]. The complex nature of AD, coupled with its insidious onset and heterogeneous presentation, has historically made early diagnosis and effective management a formidable challenge for healthcare providers. In recent years, the rapid advancement of Artificial Intelligence (AI) technologies has opened new avenues for addressing these challenges. AI, encompassing machine learning, deep learning, and natural language processing, offers unprecedented opportunities to analyze vast amounts of complex medical data, identify subtle patterns, and generate insights that may elude human experts [2]. This convergence of AI and neuroscience has the potential to transform our approach to AD, from risk prediction and early detection to personalized treatment strategies and drug discovery.

Alzheimer's disease is the most common form of dementia, accounting for 60-80% of all cases [3]. It is characterized by the accumulation of amyloid-β plaques and neurofibrillary tangles in the brain, leading to progressive neuronal loss and cognitive impairment. The personal, social, and economic toll of AD is staggering, with global costs estimated to exceed $1 trillion annually [4].

Artificial Intelligence represents a paradigm shift in medical research and practice. In the context of AD, AI technologies offer several key advantages:

- Enhanced Diagnostic Accuracy: AI algorithms can analyze complex neuroimaging data, detecting subtle changes in brain structure and function that may indicate early-stage AD, even before clinical symptoms manifest [5].
- Integrated Data Analysis: Machine learning models can synthesize diverse data types, including genetic information, biomarker levels, cognitive test scores, and clinical history, to provide a more comprehensive assessment of AD risk and progression [6].

* Corresponding author: Ismail Y

Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0.

- Personalized Medicine: AI can help tailor treatment plans to individual patients by predicting disease trajectories and identifying the most effective interventions based on a patient's unique profile [7].
- Drug Discovery: AI-driven approaches are accelerating the identification of potential therapeutic targets and the development of novel AD treatments [8].

This review aims to discuss the AI applications in Alzheimer's disease research and clinical practice. We will examine the latest advancements in AI-driven neuroimaging analysis, biomarker discovery, cognitive assessment tools, and predictive modeling. Additionally, we will discuss the challenges and limitations of implementing AI in AD care, as well as the ethical considerations that must be addressed.

2. Pathophysiology

Alzheimer's disease is a complex neurodegenerative disorder characterized by a cascade of pathological changes in the brain. It mainly occurs due to the accumulation of beta-amyloid protein, which forms extracellular plaques, and the intracellular aggregation of hyperphosphorylated tau protein, resulting in neurofibrillary tangles. These hallmark features disrupt normal neuronal function and communication, leading to progressive synaptic loss and neuronal death. As the disease advances, widespread neuronal loss occurs, particularly in regions critical for memory and cognitive function, such as the hippocampus and cortex. This loss manifests as significant brain atrophy observable through neuroimaging techniques. Concurrent with these structural changes, neurotransmitter systems, especially those involving acetylcholine, become dysregulated, further compromising cognitive processes. [2-4]



Figure 1. Pathophysiology of Alzheimer's Disease

2.1. Symptoms

The symptoms of Alzheimer's disease typically emerge gradually and worsen over time. Memory loss, particularly for recent events, is often the first noticeable sign. Individuals may struggle to recall conversations, appointments, or recently learned information. As the disease progresses, cognitive difficulties expand to encompass problems with reasoning, complex task planning, and judgment. Spatial disorientation becomes common, with individuals getting lost in familiar places or misplacing items. Behavioral and psychological symptoms frequently accompany cognitive decline. These may include mood swings, increased anxiety or agitation, social withdrawal, and changes in personality. [3-5] Sleep disturbances are also common, potentially exacerbating daytime cognitive difficulties. As the disease advances, individuals often experience a decline in language abilities, struggling to find words or follow conversations.

2.2. Diagnosis

Diagnosing Alzheimer's disease involves a comprehensive approach, combining clinical assessment with advanced diagnostic tools. A thorough medical history and physical examination form the foundation, often revealing cognitive and functional decline over time. Neuropsychological testing provides a detailed evaluation of cognitive domains, quantifying deficits in memory, attention, language, and executive function. [5,6]

Neuroimaging plays a crucial role in diagnosis. Structural MRI or CT scans can reveal brain atrophy patterns characteristic of Alzheimer's disease, while also excluding other potential causes of cognitive decline, such as tumors or stroke. Functional imaging techniques, like FDG-PET, offer insights into brain metabolism, often showing reduced activity in affected regions before structural changes are apparent.

Biomarker analysis has revolutionized Alzheimer's diagnosis, allowing for detection of disease-related changes even in pre-symptomatic stages. Cerebrospinal fluid analysis measuring levels of beta-amyloid, total tau, and phosphorylated tau can provide evidence of ongoing pathological processes. More recently, blood-based biomarkers, such as plasma p-tau181, have shown promise as less invasive diagnostic tools. [8]

In some cases, genetic testing may be considered, particularly for individuals with a strong family history of early-onset Alzheimer's disease. While most cases are sporadic, certain genetic mutations (e.g., in APP, PSEN1, or PSEN2 genes) are associated with familial forms of the disease. It's important to note that while these diagnostic methods have greatly improved our ability to identify Alzheimer's disease, a definitive diagnosis can only be confirmed through post-mortem brain examination. However, the combination of clinical presentation, cognitive testing, neuroimaging, and biomarker analysis allows for a high degree of diagnostic accuracy in living individuals.[9]

3. AI-Driven Neuroimaging Analysis in Alzheimer's Disease

Neuroimaging plays a crucial role in the diagnosis and monitoring of Alzheimer's disease. AI technologies have significantly enhanced our ability to extract meaningful information from complex imaging data, leading to more accurate and earlier detection of AD-related brain changes (illustrated in Figure 2).



Figure 2. Alzheimer's disease detection using artificial intelligence techniques.

3.1. Magnetic Resonance Imaging (MRI)

MRI provides detailed structural information about the brain, allowing for the assessment of atrophy patterns characteristic of AD. AI algorithms, particularly deep learning models, have shown remarkable success in analyzing MRI data:

3.1.1 Volumetric Analysis: Convolutional Neural Networks (CNNs) can automatically segment brain regions and quantify volumetric changes, detecting early signs of hippocampal atrophy and cortical thinning [9].

3.1.2 Texture Analysis: Machine learning algorithms can identify subtle changes in brain tissue texture that may indicate early AD pathology, even before significant atrophy is apparent [10].

3.1.3 Longitudinal Studies: AI models can track changes in brain structure over time, providing insights into disease progression and potentially predicting future cognitive decline [11].

3.2. Positron Emission Tomography (PET)

PET imaging allows for the visualization of specific molecular targets in the brain, such as amyloid-β and tau proteins. AI has enhanced the interpretation of PET scans:

3.2.1 Amyloid PET Analysis: Deep learning models can accurately quantify amyloid burden and identify patterns of deposition associated with AD [12].

3.2.2 Tau PET Analysis: AI algorithms can map the spread of tau pathology, which correlates closely with cognitive decline in AD [13].

3.2.3 Multimodal Integration: Machine learning approaches can combine PET and MRI data to provide a more comprehensive assessment of AD pathology [14].

3.3. Functional MRI (fMRI)

fMRI provides insights into brain activity and connectivity. AI techniques have improved our understanding of functional changes in AD:

3.3.1 Resting-State Networks: Machine learning models can identify alterations in resting-state functional connectivity associated with AD, potentially serving as early biomarkers [15].

3.3.2 Task-Based fMRI: AI algorithms can detect subtle changes in brain activation patterns during cognitive tasks, which may indicate early functional deficits in AD [16]

4. AI in Biomarker Discovery and Analysis

Biomarkers play a critical role in the early detection and monitoring of AD. AI technologies have accelerated the discovery of novel biomarkers and improved the analysis of existing ones.

4.1. Blood-Based Biomarkers

Recent advances have focused on developing blood-based biomarkers for AD, which are less invasive and more cost-effective than CSF analysis or neuroimaging.

4.1.1 Proteomic Profiling: Machine learning algorithms can analyze complex proteomic data to identify blood protein signatures associated with AD risk and progression [17].

4.1.2 Metabolomics: AI-driven metabolomic analyses have revealed novel metabolic markers that may serve as early indicators of AD [18].

4.1.3 Micro-RNA Analysis: Deep learning models can identify patterns of circulating micro-RNAs that correlate with AD pathology and cognitive decline [19].

4.2. Cerebrospinal Fluid (CSF) Biomarkers

CSF analysis remains a gold standard for AD biomarkers. AI has enhanced the interpretation of CSF data:

4.2.1 Multi-Analyte Models: Machine learning algorithms can integrate multiple CSF biomarkers (e.g., Aβ42, total tau, phosphorylated tau) to improve diagnostic accuracy [20].

4.2.2 Novel Biomarker Discovery: AI-driven data mining of CSF proteomics has led to the identification of new potential biomarkers for AD [21].

5. AI in Cognitive Assessment and Monitoring

AI technologies are revolutionizing cognitive assessment, enabling more sensitive and efficient detection of cognitive decline associated with AD.

5.1. Computerized Cognitive Testing

AI-enhanced computerized cognitive tests offer several advantages over traditional paper-and-pencil assessments:

5.1.1 Adaptive Testing: Machine learning algorithms can adapt test difficulty in real-time based on user performance, increasing sensitivity to subtle cognitive changes [22].

5.1.2 Multimodal Analysis: AI can integrate performance metrics, reaction times, and even eye-tracking data to provide a more comprehensive cognitive assessment [23].

5.2. Speech and Language Analysis

Natural Language Processing (NLP) techniques have shown promise in detecting early signs of cognitive decline through speech analysis:

5.2.1 Linguistic Markers: AI algorithms can identify changes in speech patterns, vocabulary use, and syntactic complexity that may indicate early AD [24].

5.2.2 Vocal Biomarkers: Machine learning models can analyze acoustic properties of speech to detect subtle changes associated with cognitive impairment [25].

5.3. Digital Biomarkers and Remote Monitoring

AI-powered digital tools enable continuous monitoring of cognitive function and behavior in real-world settings:

5.3.1 Smartphone-Based Assessment: AI algorithms can analyze data from smartphone usage patterns and built-in sensors to detect changes in cognitive function and behavior [26].

5.3.2 Wearable Devices: Machine learning models can process data from wearable devices to monitor sleep patterns, physical activity, and social engagement, which may serve as early indicators of AD risk [27].

6. AI in Predictive Modeling and Risk Assessment

One of the most promising applications of AI in AD research is the development of predictive models for disease risk and progression.

6.1. Genetic Risk Prediction

AI algorithms can analyze complex genetic data to assess AD risk:

6.1.1 Polygenic Risk Scores: Machine learning models can integrate information from multiple genetic variants to calculate more accurate polygenic risk scores for AD [28].

6.1.2 Gene-Environment Interactions: AI can model complex interactions between genetic and environmental factors to improve risk prediction [29].

6.2. Multimodal Prediction Models

AI enables the integration of diverse data types to create more robust predictive models:

6.2.1 Imaging-Genetics Models: Machine learning algorithms can combine neuroimaging and genetic data to predict AD risk and progression [30].

6.2.2 Comprehensive Risk Models: AI can integrate clinical, genetic, biomarker, and lifestyle data to provide personalized risk assessments and predict disease trajectories [31].

Table 1. Summary of AI Applications in Alzheimer's Disease Research and Clinical Practice

Domain	AI Application	Potential Impact
Neuroimaging	- Automated segmentation and volumetry - Texture analysis - Multimodal integration	- Earlier detection of structural changes - Improved diagnostic accuracy - Better monitoring of disease progression
Biomarkers	- Blood-based biomarker discovery - CSF biomarker analysis - Integration of multiple biomarkers	- Less invasive diagnostic tools - Identification of novel biomarkers - More accurate disease staging
Cognitive Assessment	- Adaptive computerized testing - Speech and language analysis - Digital biomarkers	- More sensitive cognitive assessments - Early detection of subtle cognitive changes - Continuous monitoring in real-world settings
Predictive Modeling	- Genetic risk prediction - Multimodal risk models - Personalized progression forecasting	- More accurate risk stratification - Personalized prevention strategies - Improved clinical trial design

7. Conclusion

Artificial Intelligence is rapidly transforming the landscape of Alzheimer's disease research and clinical practice. From enhancing neuroimaging analysis and biomarker discovery to enabling more sensitive cognitive assessments and personalized risk prediction, AI technologies offer unprecedented opportunities to improve the early detection, diagnosis, and management of AD. As the research continue to advance in this field, it is crucial to address the challenges of data quality, model interpretability, and ethical considerations. With continued research and collaborative efforts between clinicians, data scientists, and ethicists, AI has the potential to significantly impact the lives of millions affected by Alzheimer's disease, offering hope for earlier intervention, more effective treatments, and ultimately, better patient outcomes

References

[1] Alzheimer's Association. (2021). 2021 Alzheimer's disease facts and figures. Alzheimer's & Dementia, 17(3), 327-406.

[2] Jiang, F., Jiang, Y., Zhi, H., Dong, Y., Li, H., Ma, S., ... & Wang, Y. (2017). Artificial intelligence in healthcare: past, present and future. Stroke and Vascular Neurology, 2(4), 230-243.

[3] Scheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., Chételat, G., Teunissen, C. E., ... & van der Flier, W. M. (2021). Alzheimer's disease. The Lancet, 397(10284), 1577-1590.

[4] Wimo, A., Guerchet, M., Ali, G. C., Wu, Y. T., Prina, A. M., Winblad, B., ... & Prince, M. (2017). The worldwide costs of dementia 2015 and comparisons with 2010. Alzheimer's & Dementia, 13(1), 1-7.

[5] Feng, R., Yang, F., Wu, X., Lu, J., & Nie, D. (2022). Artificial intelligence in Alzheimer's disease neuroimaging: A review of machine learning methods. Frontiers in Aging Neuroscience, 14, 853711.

[6] Lombardi, A., Amoroso, N., Diacono, D., Monaco, A., Tangaro, S., & Bellotti, R. (2020). Explainable deep learning for personalized age prediction with brain morphology. Frontiers in Neuroscience, 14, 564212.

[7] Moreira, L. B., & Namen, A. A. (2018). A hybrid data mining model for diagnosis of patients with clinical suspicion of dementia. Computer methods and programs in biomedicine, 165, 139-149.

[8] Zhavoronkov, A., Ivanenkov, Y. A., Aliper, A., Veselov, M. S., Aladinskiy, V. A., Aladinskaya, A. V., ... & Zhebrak, A. (2019). Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nature biotechnology, 37(9), 1038-1040.

[9] Wen, J., Thibeau-Sutre, E., Diaz-Melo, M., Samper-González, J., Routier, A., Bottani, S., ... & Colliot, O. (2020). Convolutional neural networks for classification of Alzheimer's disease: Overview and reproducible evaluation. Medical Image Analysis, 63, 101694.

[10] Luk, C. C., Ishaque, A., Khan, M., Ta, D., Chenji, S., Yang, Y. H., ... & Kalra, S. (2018). Alzheimer's disease: 3-Dimensional MRI texture for prediction of conversion from mild cognitive impairment. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 10, 755-763.

[11] Li, H., Habes, M., Wolk, D. A., Fan, Y., & Alzheimer's Disease Neuroimaging Initiative. (2019). A deep learning model for early prediction of Alzheimer's disease dementia based on hippocampal magnetic resonance imaging data. Alzheimer's & Dementia, 15(8), 1059-1070.

[12] Lu, D., Popuri, K., Ding, G. W., Balachandar, R., & Beg, M. F. (2018). Multimodal and multiscale deep neural networks for the early diagnosis of Alzheimer's disease using structural MR and FDG-PET images. Scientific reports, 8(1), 1-13.

[13] Kang, D. W., Choi, W. H., Jung, W. S., Um, Y. H., Lee, C. U., & Lim, H. K. (2020). Impact of amyloid and tau PET imaging on clinical decision making in mild cognitive impairment. Clinical Nuclear Medicine, 45(8), e391-e396.

[14] Liu, M., Cheng, D., Wang, K., & Wang, Y. (2018). Multi-modality cascaded convolutional neural networks for Alzheimer's disease diagnosis. Neuroinformatics, 16(3), 295-308.

[15] Khazaee, A., Ebrahimzadeh, A., & Babajani-Feremi, A. (2017). Classification of patients with MCI and AD from healthy controls using directed graph measures of resting-state fMRI. Behavioural brain research, 322, 339-350.

[16] Suk, H. I., Wee, C. Y., Lee, S. W., & Shen, D. (2016). State-space model with deep learning for functional dynamics estimation in resting-state fMRI. NeuroImage, 129, 292-307.

[17] Westwood, S., Baird, A. L., Hye, A., Ashton, N. J., Nevado-Holgado, A. J., Anand, S. N., ... & Lovestone, S. (2018). Plasma protein biomarkers for the prediction of CSF amyloid and tau and [18F]-flutemetamol PET scan result. Frontiers in aging neuroscience, 10, 409.

[18] Varma, V. R., Oommen, A. M., Varma, S., Casanova, R., An, Y., Andrews, R. M., ... & Thambisetty, M. (2018). Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study. PLoS medicine, 15(1), e1002482.

[19] Sheinerman, K. S., Tsivinsky, V. G., Abdullah, L., Crawford, F., & Umansky, S. R. (2013). Plasma microRNA biomarkers for detection of mild cognitive impairment: biomarker validation study. Aging (Albany NY), 5(12), 925.

[20] Galasko, D., Shaw, L. M., Alcolea, D., Blennow, K., Fagan, A. M., Zetterberg, H., ... & Mattsson, N. (2022). Comparison of CSF biomarkers in the Alzheimer's disease continuum. Alzheimer's & Dementia, 18(5), 953-965.

[21] Bader, J. M., Geyer, P. E., Müller, J. B., Strauss, M. T., Koch, M., Leypoldt, F., ... & Mann, M. (2020). Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease. Molecular systems biology, 16(6), e9356.

[22] Asgari, M., Kaye, J., & Dodge, H. (2017). Predicting mild cognitive impairment from spontaneous spoken utterances. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 3(2), 219-228.

[23] Dodge, H. H., Zhu, J., Mattek, N. C., Austin, D., Kornfeld, J., & Kaye, J. A. (2015). Use of high-frequency in-home monitoring data may reduce sample sizes needed in clinical trials. PloS one, 10(9), e0138095.

[24] Fraser, K. C., Meltzer, J. A., & Rudzicz, F. (2016). Linguistic features identify Alzheimer's disease in narrative speech. Journal of Alzheimer's Disease, 49(2), 407-422.

[25] König, A., Satt, A., Sorin, A., Hoory, R., Toledo-Ronen, O., Derreumaux, A., ... & David, R. (2015). Automatic speech analysis for the assessment of patients with predementia and Alzheimer's disease. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 1(1), 112-124.

[26] Kourtis, L. C., Regele, O. B., Wright, J. M., & Jones, G. B. (2019). Digital biomarkers for Alzheimer's disease: the mobile/wearable devices opportunity. NPJ digital medicine, 2(1), 1-9.

[27] Sarella PN, Mangam VT. AI-Driven Natural Language Processing in Healthcare: Transforming Patient-Provider Communication. Indian Journal of Pharmacy Practice. 2024;17(1).

[28] Escott-Price, V., Sims, R., Bannister, C., Harold, D., Vronskaya, M., Majounie, E., ... & Williams, J. (2015). Common polygenic variation enhances risk prediction for Alzheimer's disease. Brain, 138(12), 3673-3684.

[29] Batthula SA, Yandamuri NA, Divya P, Narla L, Bandam P, Allada SN. Development and Validation of RP-HPLC Method for Simultaneous Estimation of Lansoprazole and Paliperidone Palmitate in Bulk Drugs. PHARMANEST. 2015;6:2704-8.

[30] Khanna, S., Domingo-Fernández, D., Iyappan, A., Emon, M. A., Hofmann-Apitius, M., & Fröhlich, H. (2018). Using multi-scale genetic, neuroimaging and clinical data for predicting Alzheimer's disease and reconstruction of relevant biological mechanisms. Scientific reports, 8(1), 1-13.

[31] Ansart, M., Epelbaum, S., Bassignana, G., Bône, A., Bottani, S., Cattai, T., ... & Colliot, O. (2021). Predicting the progression of mild cognitive impairment using machine learning: A systematic, quantitative and critical review. Medical Image Analysis, 67, 101848.